Initial series of magnetic resonance imaging (MRI)‐fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA
Objectives To describe a step‐by‐step guide for using the first transperineal targeted prostate biopsy platform available in the USA. Patients and Methods A total of 32 men with elevated prostate‐specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic reson...
Gespeichert in:
| Veröffentlicht in: | BJU international 2018-11, Vol.122 (5), p.909-912 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 912 |
|---|---|
| container_issue | 5 |
| container_start_page | 909 |
| container_title | BJU international |
| container_volume | 122 |
| creator | Kosarek, Christopher D. Mahmoud, Ali M. Eyzaguirre, Eduardo J. Shan, Yong Walser, Eric M. Horn, Gary L. Williams, Stephen B. |
| description | Objectives
To describe a step‐by‐step guide for using the first transperineal targeted prostate biopsy platform available in the USA.
Patients and Methods
A total of 32 men with elevated prostate‐specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications.
Results
The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri‐operative complications.
Conclusion
These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa. |
| doi_str_mv | 10.1111/bju.14206 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2018020387</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2018020387</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-c34a6e5cc46587c22b7c166de5e56d4cf76677f476b58a01695a78087bc267a43</originalsourceid><addsrcrecordid>eNp1kc9uEzEQxi1U1JbSAy9QWeqlPaS1Hf_LsVQUgoqQgEjcLK8zmzraeIPtpcqNR-DK6_EkDE1LpUr4YI_Gv_nGno-QV5ydcVznzXI441Iw_Yzsc6nlSHL2dechZhO9R16UsmQME1rtkj0xUXoy5nyf_JqmWKPvaIEcodC-pSu_SFBjoBlKn3wKQCPmYlrQkw-fpqe_f_xshxL7RKvPC6gwp-vcl-or0Cb267KheI10vQHaxlwqrdmnssYOCbDVY1nna9vnFfXffex802GndFc2-3zxkjxvfVfg8P48ILOrN18u342uP76dXl5cj8LYWo279BpUCFIra4IQjQlc6zkoUHouQ2u0NqaVRjfKesb1RHljmTVNENp4OT4gJ1td_MS3AUp1q1gCdJ1P0A_FCcYtE2xsDaLHT9BlP-SEr3OCC2m5lEwhdbqlAk6lZGjdOuMA88Zx5v765dAvd-cXskf3ikOzgvk_8sEgBM63wG3sYPN_Jff6_Wwr-Qc9rKFW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2124814405</pqid></control><display><type>article</type><title>Initial series of magnetic resonance imaging (MRI)‐fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Kosarek, Christopher D. ; Mahmoud, Ali M. ; Eyzaguirre, Eduardo J. ; Shan, Yong ; Walser, Eric M. ; Horn, Gary L. ; Williams, Stephen B.</creator><creatorcontrib>Kosarek, Christopher D. ; Mahmoud, Ali M. ; Eyzaguirre, Eduardo J. ; Shan, Yong ; Walser, Eric M. ; Horn, Gary L. ; Williams, Stephen B.</creatorcontrib><description>Objectives
To describe a step‐by‐step guide for using the first transperineal targeted prostate biopsy platform available in the USA.
Patients and Methods
A total of 32 men with elevated prostate‐specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications.
Results
The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri‐operative complications.
Conclusion
These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.</description><identifier>ISSN: 1464-4096</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/bju.14206</identifier><identifier>PMID: 29569311</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Biopsy ; Humans ; Image processing ; Image-Guided Biopsy - methods ; Magnetic resonance imaging ; Magnetic Resonance Imaging, Interventional - methods ; Male ; NMR ; Nuclear magnetic resonance ; Patient Positioning ; Prostate - diagnostic imaging ; Prostate - pathology ; prostate biopsy ; Prostate cancer ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - pathology ; Surveillance ; targeted ; transperineal ; Ultrasound ; UroNav ; White people</subject><ispartof>BJU international, 2018-11, Vol.122 (5), p.909-912</ispartof><rights>2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd</rights><rights>2018 The Authors BJU International © 2018 BJU International Published by John Wiley & Sons Ltd.</rights><rights>BJUI © 2018 BJU International</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-c34a6e5cc46587c22b7c166de5e56d4cf76677f476b58a01695a78087bc267a43</citedby><cites>FETCH-LOGICAL-c3886-c34a6e5cc46587c22b7c166de5e56d4cf76677f476b58a01695a78087bc267a43</cites><orcidid>0000-0003-1701-5578 ; 0000-0002-2683-2185</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbju.14206$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbju.14206$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29569311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kosarek, Christopher D.</creatorcontrib><creatorcontrib>Mahmoud, Ali M.</creatorcontrib><creatorcontrib>Eyzaguirre, Eduardo J.</creatorcontrib><creatorcontrib>Shan, Yong</creatorcontrib><creatorcontrib>Walser, Eric M.</creatorcontrib><creatorcontrib>Horn, Gary L.</creatorcontrib><creatorcontrib>Williams, Stephen B.</creatorcontrib><title>Initial series of magnetic resonance imaging (MRI)‐fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Objectives
To describe a step‐by‐step guide for using the first transperineal targeted prostate biopsy platform available in the USA.
Patients and Methods
A total of 32 men with elevated prostate‐specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications.
Results
The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri‐operative complications.
Conclusion
These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.</description><subject>Aged</subject><subject>Biopsy</subject><subject>Humans</subject><subject>Image processing</subject><subject>Image-Guided Biopsy - methods</subject><subject>Magnetic resonance imaging</subject><subject>Magnetic Resonance Imaging, Interventional - methods</subject><subject>Male</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Patient Positioning</subject><subject>Prostate - diagnostic imaging</subject><subject>Prostate - pathology</subject><subject>prostate biopsy</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Surveillance</subject><subject>targeted</subject><subject>transperineal</subject><subject>Ultrasound</subject><subject>UroNav</subject><subject>White people</subject><issn>1464-4096</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uEzEQxi1U1JbSAy9QWeqlPaS1Hf_LsVQUgoqQgEjcLK8zmzraeIPtpcqNR-DK6_EkDE1LpUr4YI_Gv_nGno-QV5ydcVznzXI441Iw_Yzsc6nlSHL2dechZhO9R16UsmQME1rtkj0xUXoy5nyf_JqmWKPvaIEcodC-pSu_SFBjoBlKn3wKQCPmYlrQkw-fpqe_f_xshxL7RKvPC6gwp-vcl-or0Cb267KheI10vQHaxlwqrdmnssYOCbDVY1nna9vnFfXffex802GndFc2-3zxkjxvfVfg8P48ILOrN18u342uP76dXl5cj8LYWo279BpUCFIra4IQjQlc6zkoUHouQ2u0NqaVRjfKesb1RHljmTVNENp4OT4gJ1td_MS3AUp1q1gCdJ1P0A_FCcYtE2xsDaLHT9BlP-SEr3OCC2m5lEwhdbqlAk6lZGjdOuMA88Zx5v765dAvd-cXskf3ikOzgvk_8sEgBM63wG3sYPN_Jff6_Wwr-Qc9rKFW</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Kosarek, Christopher D.</creator><creator>Mahmoud, Ali M.</creator><creator>Eyzaguirre, Eduardo J.</creator><creator>Shan, Yong</creator><creator>Walser, Eric M.</creator><creator>Horn, Gary L.</creator><creator>Williams, Stephen B.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1701-5578</orcidid><orcidid>https://orcid.org/0000-0002-2683-2185</orcidid></search><sort><creationdate>201811</creationdate><title>Initial series of magnetic resonance imaging (MRI)‐fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA</title><author>Kosarek, Christopher D. ; Mahmoud, Ali M. ; Eyzaguirre, Eduardo J. ; Shan, Yong ; Walser, Eric M. ; Horn, Gary L. ; Williams, Stephen B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-c34a6e5cc46587c22b7c166de5e56d4cf76677f476b58a01695a78087bc267a43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Aged</topic><topic>Biopsy</topic><topic>Humans</topic><topic>Image processing</topic><topic>Image-Guided Biopsy - methods</topic><topic>Magnetic resonance imaging</topic><topic>Magnetic Resonance Imaging, Interventional - methods</topic><topic>Male</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Patient Positioning</topic><topic>Prostate - diagnostic imaging</topic><topic>Prostate - pathology</topic><topic>prostate biopsy</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Surveillance</topic><topic>targeted</topic><topic>transperineal</topic><topic>Ultrasound</topic><topic>UroNav</topic><topic>White people</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kosarek, Christopher D.</creatorcontrib><creatorcontrib>Mahmoud, Ali M.</creatorcontrib><creatorcontrib>Eyzaguirre, Eduardo J.</creatorcontrib><creatorcontrib>Shan, Yong</creatorcontrib><creatorcontrib>Walser, Eric M.</creatorcontrib><creatorcontrib>Horn, Gary L.</creatorcontrib><creatorcontrib>Williams, Stephen B.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kosarek, Christopher D.</au><au>Mahmoud, Ali M.</au><au>Eyzaguirre, Eduardo J.</au><au>Shan, Yong</au><au>Walser, Eric M.</au><au>Horn, Gary L.</au><au>Williams, Stephen B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Initial series of magnetic resonance imaging (MRI)‐fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2018-11</date><risdate>2018</risdate><volume>122</volume><issue>5</issue><spage>909</spage><epage>912</epage><pages>909-912</pages><issn>1464-4096</issn><eissn>1464-410X</eissn><abstract>Objectives
To describe a step‐by‐step guide for using the first transperineal targeted prostate biopsy platform available in the USA.
Patients and Methods
A total of 32 men with elevated prostate‐specific antigen (PSA) levels were diagnosed with a region of interest on multiparametric magnetic resonance imaging (mpMRI) between February 2017 and January 2018. The transperineal targeted prostate biopsy procedure was accomplished via a transperineal approach and used a stepper, combined with advanced mpMRI/transrectal ultrasound fusion software, to perform targeted prostate biopsy. The detection of overall and clinically significant prostate cancer (PCa) was assessed as well as the rate of complications.
Results
The median patient age was 68.0 years and the median PSA was 8.0 ng/mL. Two patients (6%) were active surveillance candidates and 16 (50%) had a prior negative prostate biopsy. The detection rates for overall and clinically significant PCa were 81% and 59%, respectively. The two candidates for active surveillance and eight of the patients with a prior negative prostate biopsy had clinically significant PCa confirmed on targeted biopsy. There were no peri‐operative complications.
Conclusion
These results demonstrate the promising potential of the first transperineal targeted prostate biopsy platform in the USA as an alternative diagnostic method for PCa.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29569311</pmid><doi>10.1111/bju.14206</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0003-1701-5578</orcidid><orcidid>https://orcid.org/0000-0002-2683-2185</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-4096 |
| ispartof | BJU international, 2018-11, Vol.122 (5), p.909-912 |
| issn | 1464-4096 1464-410X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2018020387 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Biopsy Humans Image processing Image-Guided Biopsy - methods Magnetic resonance imaging Magnetic Resonance Imaging, Interventional - methods Male NMR Nuclear magnetic resonance Patient Positioning Prostate - diagnostic imaging Prostate - pathology prostate biopsy Prostate cancer Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Surveillance targeted transperineal Ultrasound UroNav White people |
| title | Initial series of magnetic resonance imaging (MRI)‐fusion targeted prostate biopsy using the first transperineal targeted platform available in the USA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T07%3A33%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Initial%20series%20of%20magnetic%20resonance%20imaging%20(MRI)%E2%80%90fusion%20targeted%20prostate%20biopsy%20using%20the%20first%20transperineal%20targeted%20platform%20available%20in%20the%20USA&rft.jtitle=BJU%20international&rft.au=Kosarek,%20Christopher%20D.&rft.date=2018-11&rft.volume=122&rft.issue=5&rft.spage=909&rft.epage=912&rft.pages=909-912&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/bju.14206&rft_dat=%3Cproquest_cross%3E2018020387%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2124814405&rft_id=info:pmid/29569311&rfr_iscdi=true |